ADVM – adverum biotechnologies, inc. (US:NASDAQ)
Stock Stats
News
12/1
07:00 am
advm
Low
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
11/19
06:18 pm
advm
Low
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
11/19
02:10 pm
advm
Low
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOUS, ADVM, HBAN, and COMP
11/17
08:06 am
advm
Low
Adverum Biotechnologies (NASDAQ:ADVM) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, down previously from $30.00.
11/7
08:28 am
advm
Low
Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors [Yahoo! Finance]
11/12/2025
04:08 pm
ADVM
1.0%
MISS
8/12/2025
07:00 am
ADVM
3.2%
MISS
5/14/2025
04:05 pm
ADVM
-5.1%
MISS
11/17
08:06 am
Reiterates
Buy
Neutral
HC Wainwright
Low
0.5%
11/17
06:11 am
Downgrades
BUY
NEUTRAL
H.C. WAINWRIGHT
Low
-0.7%
11/17
06:11 am
Downgrades
BUY
NEUTRAL
H.C. WAINWRIGHT
Low
-0.7%
10/28
05:30 pm
Maintains
Sector Perform
Sector Perform
RBC Capital
Low
1.0%
10/28
05:30 pm
Maintains
Sector Perform
Sector Perform
RBC Capital
Low
1.0%
12/5
04:42 pm
advm
Low
Form 3 Adverum Biotechnologies, For: Nov 25 Filed by: FHMLSP, L.P.
12/4
04:36 pm
advm
Low
Form 8-K Adverum Biotechnologies, For: Dec 04
12/3
09:42 pm
advm
Low
Form 4 Adverum Biotechnologies, For: Dec 01 Filed by: Leonard Braden Michael
12/1
07:15 am
advm
Low
Form SC 14D9/A Adverum Biotechnologies, Filed by: Adverum Biotechnologies, Inc.
11/28
03:26 pm
advm
Neutral
Form SCHEDULE 13G/A Adverum Biotechnologies, Filed by: Frazier Life Sciences Public Fund, L.P.
Show more
Top News Gainers
3/12 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 30.8%
5/16 Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD 26.0%
2/10 Form 424B5 Adverum Biotechnologies, 23.8%
7/8 Adverum Biotechnologies to Present Data at Upcoming Conferences 22.5%
2/9 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating. 21.0%
3/18 Form 4 Adverum Biotechnologies, For: Mar 17 Filed by: PATTERSON LEONE D 17.0%
10/11 Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting 15.1%
3/19 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.2%
3/25 Form 4 Adverum Biotechnologies, For: Mar 20 Filed by: PATTERSON LEONE D 9.2%
10/31 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates 8.8%
Top News Decliners
3/11 Adverum Biotechnologies Announces Data Presentations at ARVO 2020 -13.8%
3/16 Adverum Biotechnologies Inc (NASDAQ: ADVM) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating on the stock. -13.2%
8/1 Adverum Biotechnologies Announces Board and Senior Management Changes -12.6%
2/10 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $20.00 price target on the stock, up previously from $10.00. -11.8%
4/20 Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors -11.6%
3/5 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update -10.7%
9/13 Adverum Biotechnologies Inc (NASDAQ: ADVM) had its price target lowered by analysts at Chardan Capital from $10.00 to $6.00. They now have a "neutral" rating on the stock. -10.4%
4/29 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
3/11 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -9.4%
3/2 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM -9.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3